Amylyx Pharmaceuticals (NASDAQ:AMLX) is entering what it described as a pivotal year for its lead program, avexitide, with ...

Shares in Amylyx Pharmaceuticals (NASDAQ: AMLX) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a ...

Amylyx Pharmaceuticals is withdrawing its drug for amyotrophic lateral sclerosis from the market, a decision that comes a month after post-marketing clinical trial results showed the medication was no ...

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) acquired avexitide from Eiger BioPharmaceuticals Inc (OTC:EIGRQ) for $35.1 million. Avexitide is an investigational, first-in-class glucagon-like peptide-1 ...

Amylyx is a "falling knife" that many investors will have either gotten out of or shy away from. But while Amylyx's main drug failed back in March, management has taken advantage of its strong balance ...

The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient ...

Amylyx Pharmaceuticals is withdrawing its FDA-approved therapy for amyotrophic lateral sclerosis, Relyvrio, from the market after a phase 3 study failure, the company said April 4. In early March, the ...

Amylyx Pharmaceuticals (NASDAQ:AMLX) has priced a public offering of ~17.14M shares of its common stock at $3.50 a share. In addition, Amylyx has granted the underwriter a 30-day option to purchase up ...

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Wednesday decided to discontinue the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in ...

Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease. Relyvrio was approved by ...

A Wall Street company is excited about this small-cap pharmaceutical company's pipeline. The top-line phase 3 results of its key pipeline drug are expected to be available in the first half of 2026.